Search Results for US trade representative

Showing 1 – 4

US Trade Report Highlights Pharma's IP, Counterfeit Issues Abroad By Zachary Brennan - Published 01 May 2017

The Office of the United States Trade Representative's (USTR) 2017 report on the state of intellectual property (IP) protection and enforcement in US trading partners around the world offers a look into concerns regarding market access barriers, particularly for those in the pharmaceutical and medical device industries.

Categories: News, Asia, Europe, Middle East, US, Biologics and biotechnology, Drugs, Government affairs, Medical Devices, Regulatory intelligence, Regulatory strategy

Tags: US Trade Representative, IP protection, pharmaceutical IP, drug counterfeits

USTR: 97% of Counterfeit Drugs in US Shipped From Four Countries By Zachary Brennan - Published 02 May 2016

The Office of the US Trade Representative (USTR) is raising new questions in its latest special report about some trade partners’ practices of limiting imports of foreign pharmaceutical and medical devices, as well as major concerns about counterfeit drugs and devices coming from four Asian countries.

Categories: News, Asia, Europe, Middle East, US, Biologics and biotechnology, Compliance, Distribution, Drugs

Tags: US trade representative, counterfeit drugs, Indian drug counterfeits, US trade partners for pharmaceuticals

USTR: 97% of Counterfeit Drugs in US Shipped From Four Countries By Zachary Brennan - Published 02 May 2016

The Office of the US Trade Representative (USTR) is raising new questions in its latest special report about some trade partners’ practices of limiting imports of foreign pharmaceutical and medical devices, as well as major concerns about counterfeit drugs and devices coming from four Asian countries.

Categories: News, Asia, Europe, Latin America and Caribbean, Middle East, Oceania, US, Biologics and biotechnology, Compliance, Crisis management, Drugs, Government affairs

Tags: US trade representative, counterfeit drugs, Indian drug counterfeits, US trade partners for pharmaceuticals

Trade Group Wants to See Stricter Limits on Compulsory Licensing By Michael Mezher - Published 02 March 2015

A US-based trade group wants to see the United States Trade Representative (USTR) pursue stricter limits on the ability of countries to bypass patent protection. In its Special 301 Submission 2015, the Pharmaceutical Research and Manufacturers of America (PhRMA) argues that compulsory licenses should only be issued in “exceptional situations,” where there is a pressing public health need.

Categories: News, Asia, Europe, Latin America and Caribbean, US, Drugs, Government affairs, Regulatory strategy

Tags: Compulsory License, TRIPS, Intellectual Property, PhRMA, US Trade Representative